Sodium-glucose cotransporter 2 inhibitors (SGLT2is), initially developed as a medication for glucose control in type 2 diabetes (T2D), have recently emerged as a new therapeutic option for HF [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.